Eli Lilly is laying down up to $2.3 billion in cash to scoop up Ajax Therapeutics, betting that a Cambridge biotech's experimental myelofibrosis drug can beef up its oncology pipeline. Ajax's lead candidate, AJ1-11095, is an investigational once-daily oral Type II JAK2 inhibitor that is currently in early Phase 1 testing, with proof-of-concept data expected later in 2026. The acquisition agreement includes an upfront payment plus contingent milestone payouts that together could reach $2.3 billion.
Under the definitive agreement, Ajax shareholders stand to receive up to $2.3 billion in cash, a mix of an upfront payment and additional clinical and regulatory milestone payments, according to PR Newswire. Lilly, which had been a founding strategic investor in Ajax, said it plans to move quickly to push AJ1-11095 into registrational trials if the data cooperate. "We look forward to the presentation of clinical proof-of-concept data later in 2026," Jacob Van Naarden, president of Lilly Oncology, said in the release.
What Ajax's Drug Is
AJ1-11095 was engineered to bind the Type II conformation of the JAK2 enzyme, a different approach from currently approved Type I JAK2 inhibitors. Ajax says that shift in mechanism could translate into deeper, more durable disease control for patients who have stopped responding to available therapies. The company notes that the investigational medicine entered a Phase 1 study (AJX-101) in late 2024 and that dose selection for future development is expected this year, according to Ajax Therapeutics.
Why The Approach Matters
JAK inhibitors are a long-established, if imperfect, class for myeloproliferative neoplasms. They tend to ease symptoms but rarely reshape the overall disease course, and safety worries have dogged some newer candidates. Industry reporting notes that Ajax blended academic discovery with computational structure-based design and a partnership with Schrödinger to craft a more selective JAK2 inhibitor, a strategy that helped catch investors' attention, as reported by BioPharma Dive.
Deal Details And Next Steps
The transaction still has to clear the usual closing conditions, including review under the Hart-Scott-Rodino antitrust process, and the parties have already lined up legal counsel, according to the company release. Ajax co-founder and CEO Martin Vogelbaum said the team is "grateful to our clinical investigators, and most importantly, the patients who have participated in our ongoing Phase 1 study," and added that the company looks forward to Lilly advancing the program, according to PR Newswire.
For patients and hematologists, the real make-or-break moment lands with the 2026 proof-of-concept readout. If the data come in strong, Lilly's buyout could turn a small Cambridge startup into a widely available treatment option. Investors, meanwhile, will be watching how quickly Lilly folds the program into its broader oncology strategy and whether the numbers ultimately justify both registrational trials and the milestone-laden $2.3 billion price tag.
